Russ Conroy

The new drug application for rivoceranib plus camrelizumab in unresectable hepatocellular carcinoma is supported by findings from the phase 3 CARES 310 study.

The QPOLE assay may be a fast, low-cost alternative to other next-generation sequencing tools for POLE testing among patients with endometrial cancer.

Findings from the phase 3 KEYNOTE-564 trial support adjuvant pembrolizumab following nephrectomy as a standard-of-care treatment for patients with clear cell renal cell carcinoma.

The improvements occur regardless of PD-L1 status among patients receiving lenvatinib plus pembrolizumab for advanced renal cell carcinoma in the phase 3 CLEAR study.

Using a laser ablation system, imaging mass cytometry is designed to measure over 40 metal isotopes in a tumor sample to identify how immune cells in clear cell renal cell carcinoma are organized.

Factors including measurable residual disease and CAR T-cell expansion appear to predict duration of response following JCAR014 in those with relapsed or refractory chronic lymphocytic leukemia in a phase 1/2 trial.

Findings from the phase 1b KRYSTAL-1 trial support the continued development of adagrasib in the treatment of patients with KRAS G12C–mutated non–small cell lung cancer and central nervous system metastases.

Epcoritamab is a treatment option for patients with relapsed/refractory diffuse large B-cell lymphoma that was approved by the FDA based on findings from the phase 1/2 EPCORE NHL-1 trial.

Data from the phase 2 ROCKstar trial support the approval of belumosudil as a treatment for patients with chronic graft-versus-host-disease in Scotland.

Combining enfortumab vedotin with pembrolizumab yields a manageable safety profile in patients with locally advanced or metastatic urothelial cancer in the phase 1b/2 EV-103 study.

Findings from the phase 3 FRESCO-2 trial support fruquintinib plus best supportive care as a global treatment option for patients with refractory metastatic colorectal cancer.

Patients with select hematologic cancers, including lymphoma and multiple myeloma, appear to benefit from a ready-to-dilute formation of intravenous cyclophosphamide, the new drug application for which was approved by the FDA.

Data from the phase 2 MANIFEST study suggest that pelabresib plus ruxolitinib may improve the standard of care for patients with myelofibrosis who are naïve to treatment with JAK inhibitors.

The benefit of nivolumab/ipilimumab plus single-agent nivolumab for unresectable advanced melanoma with poor prognostic characteristics was comparable in all-comers and patients with brain metastases.

Hypersensitivity reactions following platinum-based treatment appear to be more severe than hypersensitivity reactions after taxanes among patients with cancer.

Overall survival is expected to continue improving among patients with glioblastoma being treated with frontline olaptesed pegol plus radiotherapy and bevacizumab who remain on the phase 1/2 GLORA study.

Use of an ixabepilone-based companion diagnostic may identify patients with metastatic breast cancer who may benefit from ixabepilone monotherapy.

The FDA sets a Prescription Drug User Fee Act date of January 12, 2024 for the biologics license application for zolbetuximab in the management of Claudin 18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

The safety profile of durvalumab plus tremelimumab among those with unresectable hepatocellular carcinoma in the phase 3 HIMALAYA trial was comparable with the known profiles of each individual agent.

Datopotamab deruxtecan produces no new safety signals among patients with locally advanced or metastatic non–small cell lung cancer in the phase 3 TROPION-Lung01 trial.

Data from the phase 1/2 eNRGy trial assessing zenocutuzumab in patients with NRG1 fusion–positive cancer support the FDA’s breakthrough therapy designation for the agent as a treatment for pancreatic cancer.

Investigators of the phase 1/2 EPCORE NHL-1 trial plan to discuss their findings with global regulatory authorities to determine the next steps for epcoritamab in the treatment of relapsed/refractory follicular lymphoma.

The oncolytic adenovirus VCN-01 is under investigation as a treatment for metastatic pancreatic ductal adenocarcinoma in the phase 2b VIRAGE trial.

An experimental cyclophosphamide-based prophylaxis regimen may also elicit a lower rate of chronic graft-versus-host-disease vs standard prophylaxis in patients with hematologic cancers.

Investigators anticipate sharing data from a phase 1/2a trial evaluating inobrodib on its own and in combination with pomalidomide and dexamethasone among patients with multiple myeloma at a future medical conference.

Data appear to support a tailored treatment approach with induction and post–autologous stem cell transplant consolidation daratumumab and CVRd in those with ultra-high–risk multiple myeloma.

Investigators expect to have a readout of topline data from the phase 2 OPTIMIZE-1 trial evaluating mitazalimab plus chemotherapy in metastatic pancreatic ductal adenocarcinoma in early 2024.

Iopromide injection becomes the first FDA-approved contrast agent for visualizing known or suspected breast lesions in adult patients.

Findings from the phase 3 ADAM VTE trial indicate that apixaban yields lower rates of major bleeding compared with dalteparin as a thromboprophylactic treatment in patients with cancer.

Treatment with liso-cel produces low rates of severe cytokine release syndrome in relapsed/refractory mantle cell lymphoma and follicular lymphoma in the phase 1 TRANSCEND NHL 001 trial and the phase 2 TRANSCEND FL trial.